| Literature DB >> 17880834 |
Abstract
Antimuscarinics are the treatment of choice for patients suffering from overactive bladder syndrome (OAB). Clinical experience and the literature support the efficacy, tolerability, and safety of each agent. With increasing data and educational and marketing efforts, many health care providers are uncertain which antimuscarinic should be prescribed first. It is important to recognize that there is not one superior agent, and that the individual response to each antimuscarinic is highly variable. This paper uses peer-reviewed literature to elucidate various agents with respect to efficacy, tolerability, and safety, to help readers understand the pros and cons associated with each drug so they may better manage patients with OAB.Entities:
Mesh:
Substances:
Year: 2007 PMID: 17880834 DOI: 10.1007/s11934-007-0032-6
Source DB: PubMed Journal: Curr Urol Rep ISSN: 1527-2737 Impact factor: 3.092